Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.88

€0.88

-2.010%
-0.018
-2.010%
€9.35

€9.35

 
19:09 / Tradegate WKN: A0LBCR / Name: Sernova / Stock / Healthcare Equipment & Supplies / Micro Cap /
Latest predictions
€12.00
15.10.21
-1.13%
buy
€9.00
15.10.21
-1.13%
buy
€9.20
13.10.21
-3.11%
buy
€9.50
13.10.21
-0.46%
buy
€10.00
13.10.21
0.23%
buy
€15.00
13.10.21
-0.23%
buy
Best running prediction
-
01.07.20
358.95%
buy
Your prediction

Sernova Corp. Stock

We can see a decrease in the price for Sernova Corp.. Compared to yesterday it has lost -€0.018 (-2.010%).
With 10 Buy predictions and not the single Sell prediction the community is currently very high on Sernova Corp..
Based on the current price of €0.88 the target price of €9.00 shows a potential of 925.057% for Sernova Corp. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Sernova Corp. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Sernova Corp. in the next few years

Pros
4
Could be very worthwhile Investment >20% year
4
Undervalued
4
Very positive Cash Flow expected
Cons
0
-

Performance of Sernova Corp. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Sernova Corp. -2.010% 2.989% -1.538% 373.073% 131.226% - -
Aequus Pharmaceuticals Inc 1.000% 0.250% -11.674% 5.526% 25.313% - -
Humanoptics AG -2.250% -6.316% -2.732% 10.559% 7.229% - -
NanoVibronix -1.410% -3.072% -22.616% - - - -

Other discussions about Sernova Corp. Stock

New thread Forum

News

Sernova: The Ultimate Combination of Two Proven Technologies as Potential Functional Cure for Type 1 Diabetes and Other Chronic Diseases

Information Session Webinar on Sernova’s Conformal Coating Immune Protection Technology with Dr. Toleikis and International Expert, Dr. Tomei Now Available on Sernova’s Website

 

 

October 1,

Sernova Engages New York-Based LifeSci Advisors as US Investor Relations Partner

Integrated Advisory and Investor Relations Program to Focus on Elevating Company’s Visibility in US Capital Markets Ahead of Projected Corporate Milestones

 

LONDON, ONTARIO – September 29,

Sernova Signs Collaboration Agreement to Advance Conformal Coated Immune Protected Therapeutic Cells for Diabetes with the University of Miami

-          Collaboration to build on positive Cell Pouch T1D Clinical Outcomes and preclinical success in Global Pharmaceutical Collaborations to develop regenerative medicine therapeutic